LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $197,400 | -6.0% | 140,000 | 0.0% | 0.05% | -14.3% |
| Q1 2023 | $210,000 | +28.2% | 140,000 | 0.0% | 0.06% | +37.0% |
| Q4 2022 | $163,800 | +3.7% | 140,000 | 0.0% | 0.05% | +9.5% |
| Q3 2022 | $158,000 | -28.5% | 140,000 | 0.0% | 0.04% | -30.0% |
| Q2 2022 | $221,000 | +2.3% | 140,000 | 0.0% | 0.06% | +7.1% |
| Q1 2022 | $216,000 | +10.2% | 140,000 | +75.0% | 0.06% | +14.3% |
| Q4 2021 | $196,000 | +10.7% | 80,000 | +6.1% | 0.05% | +16.7% |
| Q1 2021 | $177,000 | +25.5% | 75,400 | -5.8% | 0.04% | 0.0% |
| Q4 2020 | $141,000 | +58.4% | 80,000 | -15.8% | 0.04% | +44.8% |
| Q3 2020 | $89,000 | +7.2% | 95,000 | 0.0% | 0.03% | +20.8% |
| Q2 2020 | $83,000 | +5.1% | 95,000 | 0.0% | 0.02% | -27.3% |
| Q1 2020 | $79,000 | -7.1% | 95,000 | 0.0% | 0.03% | +13.8% |
| Q4 2019 | $85,000 | -8.6% | 95,000 | 0.0% | 0.03% | -17.1% |
| Q3 2019 | $93,000 | – | 95,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
| Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
| Raffles Associates | 543,590 | $1,332,000 | 1.28% |
| Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
| DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
| Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
| DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
| Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
| Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |